The Impact Of A Catheter Coating On Clinical Bacteriuria

December 27, 2022 updated by: Camstent Ltd.

A Prospective Multicentre Randomized Study To Assess The Impact Of A Catheter Coating On Clinical Bacteriuria

A prospective multicentre randomized study to assess the impact of a catheter coating on clinical bacteriuria when compared to an uncoated foley catheter.

Each participant will take part in the trial from the time the participant signs the informed consent form (ICF).

After the screening visit, the participants will be randomized to either a coated catheter or an uncoated catheter. Participants will be assigned to receive trial treatment until the catheter has been removed as per standard hospital guidelines, investigator's decision to withdraw the subject, noncompliance with trial treatment or procedures, unacceptable adverse event, or participant withdraws consent.

During the trial urine samples will be taken form the catheter port, temperature will be taken, and participants and healthcare providers will be asked to complete questionnaires.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Anticipated)

272

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Buckingham, United Kingdom
        • Recruiting
        • Stoke Mandeville Hospital
        • Principal Investigator:
          • Maurizo Belci
      • Cambridge, United Kingdom
        • Recruiting
        • Addenbrookes Hospital
        • Principal Investigator:
          • Suzanne Biers
      • London, United Kingdom
        • Recruiting
        • Royal National Orthopaedic Hospital
      • Norwich, United Kingdom
        • Recruiting
        • Norfolk & Norwich University Hospital
        • Principal Investigator:
          • Mark Rochester

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Require insertion or exchange of a catheter as a component of their routine clinical care as per hospital guidelines
  2. Patients aged 18+ years will be eligible for the study.
  3. Patient understands and is willing to participate in the study and is able to comply with study procedures and visits.

Exclusion Criteria:

  1. Patients that have or recently (within 3 weeks) had a urinary catheter and displays symptoms of current urinary tract infection.
  2. Pregnant or Breastfeeding.
  3. Patients with a potentially immunocompromised conditions (HIV)
  4. Has a known silicone allergy or sensitivity
  5. Use of investigational drug or device within four weeks prior to study entry that may interfere with this study.
  6. Any medication deemed by the Investigator to potentially interfere with the study treatment
  7. Participation in any other clinical study.
  8. Has a known bloodstream infection or an infection that requires prolonged antibiotic therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Camstent Coated Catheter
The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
Other Names:
  • Standard Care
Other: Standard Care
Foley catheter, uncoated
Uncoated Foley catheter

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in the number of days in which bacterial concentrations are greater than 10^5 CFU/mL in coated catheters, as compared to uncoated control catheters
Time Frame: 1 Year
1 Year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the number of cases experiencing Symptomatic Bacteriuria (CAUTI) coated catheters vs. uncoated controls
Time Frame: 1 Year
1 Year
Change in the number of cases receiving prophylactic or therapeutic Antibiotics during catheter use in coated catheters vs. uncoated controls
Time Frame: 1 Year
1 Year
Patient Reported Outcomes (PRO)
Time Frame: 1 Year
EQ-5D-5L questionnaire will be given to participants as well as a questionnaire asking participants on their experience using the catheter
1 Year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Prital Patel, Camstent Ltd.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 27, 2021

Primary Completion (Anticipated)

September 1, 2024

Study Completion (Anticipated)

October 1, 2024

Study Registration Dates

First Submitted

July 1, 2020

First Submitted That Met QC Criteria

July 3, 2020

First Posted (Actual)

July 8, 2020

Study Record Updates

Last Update Posted (Actual)

December 28, 2022

Last Update Submitted That Met QC Criteria

December 27, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • Cam-Cath-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bacteriuria

Clinical Trials on Camstent Coated Catheter

3
Subscribe